La vendita allo scoperto per PS International Group dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di PS International Group. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

PS International Group (NASDAQ:PSIG) Azioni, Report sulle vendite allo scoperto

PS International Group

PS International Group Ltd is a freight forwarding service provider in Hong Kong with networks across the globe. It provides air and ocean export and import freight forwarding services with optional ancillary logistics-related services such as cargo pick up, cargo handling at ports, and local transportation and warehousing-related services such as repackaging, labeling, palletization, preparation of shipping documentation, arrangement of customs clearance, and warehousing to meet the requirements of customers. The company generates the majority of its revenue from Air freight services.

PS International Group Ltd. - Ordinary Shares

PS International Group Ltd

- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52 -
- Veligrotug recently received Breakthrough Therapy Designation (BTD), supporting eligibility for Priority Review; the BTD request was based on veligrotug's (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response -
- Biologics License Application (BLA) submission for veligrotug is on track for second half 2025 -
- Actively preparing organization for planned U.S. commercial launch in 2026 -
Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug ("veli"), an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eye.
The THRIVE phase 3 clinical trial in active TED evaluated 5 infusions of veli or placebo every three weeks with primary topline analysis at week 15 and then followed patients through week 52.

News

VRDN

Viridian Therapeutics Announces Positive Long-Term Durability Data From THRIVE Phase 3 Clinical Trial Of Veligrotug In TED Patients

General

Toolstation Selects GXO As Logistics Partner In The Netherlands

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and lowers the price target from $8 to $3.

Price Target

Analyst Ratings

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $3

-- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis –
-- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases –
-- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway –
-- Study conducted at Francis Crick Institute by lead author of 2024 Nature paper that identified ETS2 as a central regulator of macrophage-driven Inflammation in IBD --
MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jpUKFDUv9SBOaAYEuDBVLMrIuE8vmhtiOpWfbossUQvn_ZgVR_ZhWKlfdYagPXw3J_EzkmVJYc5JjZ7ZCkYRpRxCeF1prBNvXpoYxY6gplo=">Pasithea Therapeutics Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced new preclinical data demonstrating that PAS-004 provides superior inhibition of ETS2-driven inflammatory responses compared to selumetinib in a human macrophage model of chronic inflammation that mimics the inflammatory milieu seen in inflammatory bowel disease (IBD).
This study was conducted at the Francis Crick Institute in London, U.K. by Dr. James Lee, a gastroenterologist and Clinician Scientist Group Leader at the Genetic Mechanisms of Disease Laboratory. Dr. Lee was the lead author of a landmark 2024 Nature paper that identified ETS2 as a master regulator of inflammatory responses in IBD, and uncovered a novel genetic mechanism behind the disease, which pointed to a new, potentially effective treatment strategy through MEK inhibition.
In this new study RNA sequencing was used to measure gene expression, with PAS-004 consistently outperforming the FDA-approved MEK inhibitor selumetinib across all tested doses (0.01 μM, 0.1 μM, and 1 μM), showing greater downregulation of ETS2 target genes, as well as experimentally validated MEK1/2 pathway genes. These data suggest more robust and durable MEK inhibition by PAS-004 under inflammatory conditions.

KTTA

Pasithea Therapeutics' New Preclinical Data Shows PAS-004 Provides Superior Inhibition Of ETS2-Driven Inflammatory Responses Compared To Selumetinib In Human Macrophage Model Of Chronic Inflammation In IBD

Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) affirms FY2025 sales outlook from $2.00 million-$5.00 million to $2.00 million-$5.00 million.

Guidance

ARBE

Arbe Robotics Affirms FY2025 Sales Guidance of $2.00M-$5.00M

Autozi Regains Nasdaq Compliance As Share Price Meets $1.00 Minimum Bid Requirement Over 14 Consecutive Trading Days

Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) reported quarterly losses of $(0.09) per share. This is a 35.71 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $40.00 thousand which missed the analyst consensus estimate of $100.00 thousand by 60.00 percent. This is a 70.80 percent decrease over sales of $137.00 thousand the same period last year.

Earnings

Earnings Misses

Arbe Robotics Q1 Adj. EPS $(0.09) Up From $(0.14) YoY, Sales $40.00K Miss $100.00K Estimate

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) sees Q2 sales of $7.000 million-$7.100 million vs $7.17 million analyst estimate.

CRGO

Freightos Sees Q2 Sales $7.000M-$7.100M vs $7.17M Est

Rosenblatt analyst Catharine Trebnick maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and maintains $235 price target.

PANW

Rosenblatt Maintains Buy on Palo Alto Networks, Maintains $235 Price Target

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) affirms FY2025 sales outlook from $29.00 million-$30.60 million to $29.00 million-$30.60 million vs $29.72 million estimate.

Freightos Affirms FY2025 Sales Guidance of $29.00M-$30.60M vs $29.72M Est

Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by 14.29 percent. This is a 27.27 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $897.06 million which beat the analyst consensus estimate of $842.53 million by 6.47 percent. This is a 24.91 percent increase over sales of $718.15 million the same period last year.

Earnings Beats

Viking Holdings Q1 Adj. EPS $(0.24) Beats $(0.28) Estimate, Sales $897.06M Beat $842.53M Estimate

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and maintains $65 price target.

Reiteration

CRSP

HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $65 Price Target

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $6.95 million which beat the analyst consensus estimate of $6.78 million by 2.48 percent. This is a 29.69 percent increase over sales of $5.36 million the same period last year.

Freightos Q1 Adj. EPS $(0.05) Beats $(0.10) Estimate, Sales $6.95M Beat $6.78M Estimate

Rosenblatt analyst Catharine Trebnick maintains 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) with a Buy and maintains $2.7 price target.

EGHT

Rosenblatt Maintains Buy on 8x8, Maintains $2.7 Price Target

PLTR

Palantir Technologies And Divergent Technologies Partner To Provide Access To Divergent's Advanced Manufacturing Capabilities Via Palantir's Software Platform

Rosenblatt analyst Blair Abernethy maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and maintains $340 price target.

ADSK

Rosenblatt Maintains Buy on Autodesk, Maintains $340 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and maintains $50 price target.

IONS

HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $50 Price Target

HC Wainwright &amp; Co. analyst Arthur He downgrades Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) from Buy to Neutral.

Downgrades

PRME

HC Wainwright & Co. Downgrades Prime Medicine to Neutral

Sonic Automotive Announces First Motorcycle Sale At Newly Launched Sturgis Harley-Davidson Dealership In Downtown Sturgis

Diversified global miner Rio Tinto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) has made the next significant step into battery metals, committing $900 million for a 49.99% stake in Chile's Salar de Maricunga, a <a target="_blank" href="https://www.benzinga.com/topic/lithium" rel="noreferrer noopener">world-class lithium project</a> controlled by the Chilean state-owned miner Codelco.
"We are honoured to be chosen as Codelco's partner to deliver a world-class project using direct lithium extraction technology in the Salar de Maricunga," Rio Tinto's CEO Jakob Stausholm <a target="_blank" href="https://www.riotinto.com/en/news/releases/2025/rio-tinto-partners-with-codelco-to-develop-lithium-project-in-chiles-salar-de-maricunga" rel="noreferrer noopener">said</a> Monday.
"Codelco is a strategic partner for Rio Tinto in Chile… we aim to bring significant investment and long-term benefits to the Atacama region as we advance Maricunga and Nuevo Cobre together."
The Salar de Maricunga, located in Chile's Atacama region, is one of the world's highest-grade undeveloped lithium brine resources and holds the potential for scalable, long-life, low-cost production. The joint venture plans to use direct lithium extraction technology to boost efficiency and reduce environmental impact, particularly regarding water usage, a critical issue in the arid zone like Northern Chile.
As part of the deal, Rio Tinto will make an initial $350 million investment to support feasibility studies and resource evaluations needed for a final investment decision. If the project proceeds to construction, another $500 million will be injected, and a $50 million bonus payment will be made if lithium production begins by the end of 2030.
Codelco Chairman Máximo Pacheco noted the deal's strategic importance for Chile's energy future.
"This project continues our lithium diversification strategy, which is essential for the energy transition, with a world-class partner in Rio Tinto that represents the most attractive option for Codelco and the country," he said.
The investment marks Rio Tinto's latest expansion into <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41203850/rio-tinto-confirms-interest-in-arcadium-lithium-shares-surge" rel="noreferrer noopener">South American lithium after acquiring</a> Arcadium Lithium for $6.7 billion last year. The new partnership in Chile deepens Rio's regional presence and strengthens its role as a global lithium player.
While Rio's lithium ambitions are growing, market conditions remain subdued, prompting sector leaders like Albemarle to pause the $1.3 billion US plant project. In Q1 2025, lithium prices hit four-year lows, driven by global oversupply and weaker-than-expected electric vehicle demand.
"We're expecting this year for the market to remain in surplus," Adam Webb, head of battery raw materials at Benchmark Mineral Intelligence, said <a target="_blank" href="https://investingnews.com/daily/resource-investing/battery-metals-investing/lithium-investing/lithium-forecast/" rel="noreferrer noopener">per</a> INN.
Webb noted that current price levels, around $10,400 per metric ton, are unsustainable, with about a third of global producers operating at a loss. However, from 2026 onward, the market is forecast to tip into deficit. Long-term projections suggest a 12–15% compound annual growth rate for lithium demand, with prices expected to rebound to support new supply development, ultimately driven by expanding EV and energy storage sectors.
Price Action: RIO share traded lower by 0.43% to $62.12 premarket at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/global/25/05/45496491/trumps-uae-deal-lands-4-billion-aluminum-hub-in-oklahoma" target="_blank" rel="noreferrer noopener">Trump's UAE Deal Lands $4 Billion Aluminum Hub In Oklahoma</a></li>
</ul>
Photo by Juan Roballo via Shutterstock

Large Cap

Financing

Commodities

Global

Markets

Rio Tinto Expands Lithium Push With $900 Million Maricunga Deal

Press Releases

PS International Group Ltd. Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

PS International Group Ltd. Announces First Half 2024 Unaudited Financial Results

PSIG

Addentax Group

C.H. Robinson Worldwide, Inc. - Common Stock

C.H. Robinson Worldwide

Callan Jmb

Freightos

Expeditors International of Washington, Inc. Common Stock

Expeditors International

FedEx

BingEx Limited - American Depositary Shares

BingEx

Freight Technologies, Inc. - Ordinary Shares

Freight Technologies

Forward Air

Globavend Holdings

GXO Logistics

Hong Kong Pharma Digital Technology Holdings Limited - Ordinary shares

Hong Kong Pharma Digital

Hub Group

Jayud Global Logistics Limited - Class A Ordinary Shares

Jayud Global Logistics

New Century Logistics (BVI) Limited - Ordinary Shares

New Century Logistics

Radiant Logistics

Shengfeng Development Limited - Class A Ordinary Shares

Shengfeng Development

United Parcel Service

ZTO Express (Cayman) Inc. American Depositary Shares, each representing one Class A ordinary share.

Comments

PS International Group

Vendite allo scoperto

PS International Group (NASDAQ:PSIG) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO